New Drugs Are Replacing Chemo for Aggressive Breast Cancer
The FDA has granted broad first-line approval for Gilead's Trodelvy, signaling a shift away from traditional chemotherapy for aggressive breast cancer.
📍 The outcome
The FDA approved Gilead's Trodelvy, also known as sacituzumab govitecan, for first-line triple-negative breast cancer. The drug was approved for use alone or in combination with Keytruda.
This development contributed to a market war for TROP2 ADCs.
Epilogue added 35d ago, after coverage quieted.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The story so far
Gilead's drug Trodelvy has received FDA approval for use in first-line triple-negative breast cancer (TNBC). The treatment may be administered alone or in combination with Keytruda.
Coverage from Endpoints News, Fierce Pharma, and Cure Today emphasizes that this move positions Trodelvy as a front-line therapy. The Wall Street Journal reports that new drugs are replacing chemotherapy for aggressive breast cancer, while FirstWord Pharma notes the drug has secured a pair of approvals in the US.
Industry focus now turns to the TROP2 ADC market, which Fierce Pharma describes as a site of ongoing competition.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 46d ago.
Who reported it (6)
- Sacituzumab Govitecan Gains First-Line TNBC Indications Medscape · 47d ago
- Gilead's Trodelvy claims a pair of breast cancer approvals in the US FirstWord Pharma · 47d ago
- FDA backs Gilead’s Trodelvy for first-line, triple-negative breast cancer Endpoints News · 47d ago
- FDA Approves Trodelvy Alone or With Keytruda for First-Line Triple-Negative Breast Cancer Cure Today · 47d ago
- Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war Fierce Pharma · 47d ago
- New Drugs Are Replacing Chemo for Aggressive Breast Cancer WSJ · 47d ago broke it first
The obvious questions
What is Trodelvy approved for?
It is FDA-approved for first-line triple-negative breast cancer (TNBC).
Can Trodelvy be used with other medications?
Yes, it is approved for use alone or in combination with Keytruda.
Who manufactures Trodelvy?
The drug is produced by Gilead.
People, places & organizations
Topics
Related trends
Taylor Farms Voluntarily Recalls Fresh Jalapeños Over Salmonella Concerns
Taylor Farms recalls ready-to-eat foods and jalapeño products over salmonella concerns.
FDA approves 1st mRNA flu shot, from Moderna
The first mRNA-based influenza vaccine has received federal approval in the United States.
Breast cancer checks missing most women under 50 who are at risk, says study
Study finds NHS breast cancer guidelines miss 95% of high‑risk women under 50, sparking calls for review.
The FDA Issued a Recall on Thyroid Medication Nationwide
The FDA has issued a nationwide recall of levothyroxine sodium tablets due to the drug being described as subpotent.
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics shares are plummeting after FDA staff disputed the company's claims of Phase 3 success for its DMD cell therapy.
Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
Capricor Therapeutics shares have plunged after FDA staff raised concerns regarding the efficacy and data of its Duchenne heart disease therapy.